logo
  

Credit Suisse Group Loans Draw U.S. Fed Scrutiny : WSJ

The U.S. Federal Reserve demanded Swiss lender Credit Suisse Group AG (CS) to immediately address problems with its underwriting and sale of leveraged loans, or high-interest-rate loans used by private-equity firms and others to finance purchases of companies, among other uses, the Wall Street Journal reported citing a person familiar with the matter.

The report indicated that the Swiss bank received a letter from the Federal Reserve in recent weeks. The letter to Credit Suisse, known as a Matters Requiring Immediate Attention, found problems with the bank's adherence to guidance issued last year, warning banks to avoid deals that included too much debt or too few protections for the lenders in case of a default.

Credit Suisse has underwritten or sold close to $9 billion of loans marketed to U.S. investors for the purposes of leveraged buyouts in the year to date, giving it a market-dominating 13.4% share, the report said citing data provider Dealogic.

According to the report, the Fed's letter to Credit Suisse comes as regulators, some of whom have been taken aback by the lack of response to their guidance, are preparing to take tougher action against firms that don't follow Washington's marching orders.

It is unclear if other banks beyond Credit Suisse have received such a letter.

Officials at the Fed and the Office of the Comptroller of the Currency are using private communications with banks to rein in relaxed underwriting and debt-laden deals.

Among the options in the regulators' arsenal: issuing warning letters like the one sent to Credit Suisse or lowering a bank's supervisory rating, a move that could lead to limits on asset growth. If less formal actions fail, regulators have the power to issue cease-and-desist orders that carry the risk of fines, up to a maximum of $1 million a day, the report said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT